Literature DB >> 20499354

Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism.

Delmar M Lourenço1, Flavia L Coutinho, Rodrigo A Toledo, Fabio L M Montenegro, Joya E M Correia-Deur, Sergio P A Toledo.   

Abstract

Differences in bone mineral density (BMD) patterns have been recently reported between multiple endocrine neoplasia type 1-related primary hyperparathyroidism (HPT/MEN1) and sporadic primary HPT. However, studies on the early and later outcomes of bone/renal complications in HPT/MEN1 are lacking. In this cross-sectional study, performed in a tertiary academic hospital, 36 patients cases with uncontrolled HPT from 8 unrelated MEN1 families underwent dual-energy X-ray absorptiometry (DXA) scanning of the proximal one-third of the distal radius (1/3DR), femoral neck, total hip, and lumbar spine (LS). The mean age of the patients was 38.9 ± 14.5 years. Parathyroid hormone (PTH)/calcium values were mildly elevated despite an overall high percentage of bone demineralization (77.8%). In the younger group (<50 years of age), demineralization in the 1/3DR was more frequent, more severe, and occurred earlier (40%; Z-score -1.81 ± 0.26). The older group (>50 years of age) had a higher frequency of bone demineralization at all sites (p < .005) and a larger number of affected bone sites (p < .0001), and BMD was more severely compromised in the 1/3DR (p = .007) and LS (p = .002). BMD values were lower in symptomatic (88.9%) than in asymptomatic HPT patients (p < .006). Patients with long-standing HPT (>10 years) and gastrinoma/HPT presented significantly lower 1/3DR BMD values. Urolithiasis occurred earlier (<30 years) and more frequently (75%) and was associated with related renal comorbidities (50%) and renal insufficiency in the older group (33%). Bone mineral- and urolithiasis-related renal complications in HPT/MEN1 are early-onset, frequent, extensive, severe, and progressive. These data should be considered in the individualized clinical/surgical management of patients with MEN1-associated HPT.
© 2010 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Year:  2010        PMID: 20499354     DOI: 10.1002/jbmr.125

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  33 in total

1.  Parathyroid gland: Hyperparathyroidism in MEN1 syndrome: time to operate?

Authors:  Maria Luisa Brandi
Journal:  Nat Rev Endocrinol       Date:  2010-11       Impact factor: 43.330

Review 2.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

Review 3.  Multiple endocrine neoplasia type 1 revealed by a hip pathologic fracture.

Authors:  Maroua Slouma; Maissa Abbes; Rim Dhahri; Noureddine Litaiem; Nour Gueddiche; Nada Mansouri; Issam Msekni; Imen Gharsallah; Leila Metoui; Bassem Louzir
Journal:  Clin Rheumatol       Date:  2020-07-14       Impact factor: 2.980

4.  Impaired geometry, volumetric density, and microstructure of cortical and trabecular bone assessed by HR-pQCT in both sporadic and MEN1-related primary hyperparathyroidism.

Authors:  W Wang; M Nie; Y Jiang; M Li; X Meng; X Xing; O Wang; W Xia
Journal:  Osteoporos Int       Date:  2019-10-23       Impact factor: 4.507

Review 5.  MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics.

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Neuroendocrinology       Date:  2015-01-09       Impact factor: 4.914

6.  Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up.

Authors:  Bas A Twigt; Anouk Scholten; Gerlof D Valk; Inne H M Borel Rinkes; Menno R Vriens
Journal:  Orphanet J Rare Dis       Date:  2013-04-01       Impact factor: 4.123

Review 7.  Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1.

Authors:  Flavia L Coutinho; Delmar M Lourenco; Rodrigo A Toledo; Fabio L M Montenegro; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 8.  Surgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Marcel Cerqueira Cesar Machado
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 9.  Pituitary tumors in patients with MEN1 syndrome.

Authors:  Luis V Syro; Bernd W Scheithauer; Kalman Kovacs; Rodrigo A Toledo; Francisco J Londoño; Leon D Ortiz; Fabio Rotondo; Eva Horvath; Humberto Uribe
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 10.  Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1.

Authors:  Delmar M Lourenço; Flavia L Coutinho; Rodrigo A Toledo; Tatiana Denck Gonçalves; Fabio L M Montenegro; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.